New COVID-19 Vaccines Should Protect Against BA.2.86 and EG.5, Early Research Shows

The FDA has recently approved new COVID-19 vaccines from Pfizer and Moderna, specifically designed to target Omicron XBB.1.5. While this variant is no longer the dominant strain in the U.S., these vaccines show efficacy against newer, circulating variants such as BA.2.86 and EG.5. Researchers have noted that these updated vaccines could provide protection against emerging strains, thanks to their broader coverage.

Addressing New Variants: BA.2.86 and EG.5

BA.2.86, also known as Pirola, is a newer strain of concern with over 30 mutations. Though less than 1% of U.S. COVID-19 cases are linked to this variant, it has raised concerns due to its ability to potentially evade immunity from previous vaccinations. However, experts are still debating whether the many mutations in BA.2.86 could help it bypass the antibodies produced by the new vaccines. Meanwhile, the EG.5 variant, referred to as “Eris,” has become more prevalent, accounting for up to 44% of recent U.S. COVID-19 cases.

Efficacy of the New Vaccines

Moderna’s updated vaccine showed promising results in early testing. In a study involving 20 participants, those who received the new vaccine (as a fifth dose after their initial vaccinations and boosters) displayed robust antibody responses against BA.2.86, EG.5.1, and FL.1.5.1. These antibody levels were comparable to those produced against the original XBB.1.5 strain, indicating broad protection across variants.

Pfizer also reported that its updated vaccine generated a strong neutralizing antibody response against variants like EG.5.1 and BA.2.86. Early findings from a Novavax study suggested similar results, though the company has yet to receive FDA approval for its new vaccine.

Variant Behavior and Spread

Studies indicate that BA.2.86 has a higher potential to evade immunity, but it is less infectious than other variants, such as EG.5.1. Despite its ability to bypass antibodies in some individuals, it is still significantly less transmissible. The World Health Organization (WHO) has yet to categorize BA.2.86 as a “variant of concern,” though this could change if further data shows more risk.

The Role of Immunity in Protection

Over 97% of Americans have some degree of immunity against COVID-19, either through past infections or vaccinations. Even if the new vaccines do not completely prevent infection with the latest variants, they are expected to provide strong protection against severe illness, hospitalization, and death.

What’s Next for COVID-19 Vaccines?

Pending CDC approval, the updated Moderna and Pfizer vaccines will soon be available for those looking to protect themselves from newer COVID-19 variants. These vaccines, while originally developed for XBB.1.5, have shown enough effectiveness against emerging strains like BA.2.86 and EG.5 to provide significant public health benefits.

For the latest updates on COVID-19 and vaccine efficacy, keep an eye on health news outlets and official government sources.

Frequently Asked Questions:

• How effective are the new vaccines? The new vaccines are designed to provide protection against both older and newer variants, including BA.2.86 and EG.5, showing encouraging results in early research.

• Can the new vaccines prevent infection? While they may not completely prevent infection, the updated vaccines are expected to reduce the severity of illness caused by newer variants.

Expert Tips: Stay informed about the latest vaccine developments and consult with healthcare professionals to make the best decision for your health.

Key Takeaways: The newly approved COVID-19 vaccines from Moderna and Pfizer show promise in combating newer variants like BA.2.86 and EG.5. These vaccines will soon be available to help reduce the spread and severity of COVID-19, especially in light of emerging strains.

Join Our Community: Stay updated on the latest health news and insights by subscribing to our newsletter.